|
US7365093B2
(en)
*
|
1994-08-19 |
2008-04-29 |
Abbott Laboratories |
Endothelin antagonists
|
|
GB0004297D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
|
US6686477B2
(en)
*
|
2000-09-29 |
2004-02-03 |
Eastman Chemical Company |
Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
|
|
US20040116505A1
(en)
*
|
2001-02-23 |
2004-06-17 |
Gregory Krauss |
Treatment of tics, tremors and related disorders
|
|
JP4334344B2
(ja)
*
|
2001-08-10 |
2009-09-30 |
ユセベ ファルマ ソシエテ アノニム |
オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
|
|
AU2002340971B2
(en)
*
|
2001-10-08 |
2007-04-26 |
Ucb |
Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
|
|
CN1604776A
(zh)
|
2001-10-16 |
2005-04-06 |
记忆药物公司 |
作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
|
|
WO2003094913A1
(en)
*
|
2002-05-14 |
2003-11-20 |
Ucb, S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
|
|
CN1735459A
(zh)
*
|
2003-01-13 |
2006-02-15 |
Ucb公司 |
氢化催化剂
|
|
CA2515090A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Teva Pharmaceutical Industries Ltd |
Process for producing levetiracetam
|
|
ES2214147B1
(es)
|
2003-02-28 |
2005-10-01 |
Farma-Lepori S.A. |
Procedimiento de obtencion de un agente antiepileptico.
|
|
US20050143445A1
(en)
*
|
2003-03-18 |
2005-06-30 |
Parthasaradhi Reddy B. |
Novel crystalline forms of levetiracetam
|
|
RU2232578C1
(ru)
*
|
2003-04-10 |
2004-07-20 |
Ахапкина Валентина Ивановна |
Вещество, обладающее антидепрессивной активностью
|
|
EP1613590A2
(en)
|
2003-04-16 |
2006-01-11 |
Memory Pharmaceutical Corporation |
4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
|
|
US7034051B2
(en)
*
|
2003-08-28 |
2006-04-25 |
Adolor Corporation |
Fused bicyclic carboxamide derivatives and methods of their use
|
|
EP1663968A1
(en)
*
|
2003-09-05 |
2006-06-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of pure levetiracetam
|
|
KR101124098B1
(ko)
*
|
2003-09-24 |
2012-03-21 |
유씨비 파마, 에스.에이. |
2-옥소-1-피롤리딘 유도체를 제조하는 방법
|
|
EA010031B1
(ru)
|
2003-12-02 |
2008-06-30 |
Юсб, С.А. |
Производные имидазола, способы их получения и применения
|
|
WO2005121082A1
(en)
*
|
2004-06-11 |
2005-12-22 |
Ucb, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
|
MXPA06014228A
(es)
*
|
2004-06-21 |
2007-02-14 |
Warner Lambert Co |
Preparacion de pregabalina y compuestos relacionados.
|
|
US7427601B2
(en)
*
|
2004-06-24 |
2008-09-23 |
Schwarz Pharma Ag |
Method for treating tremor
|
|
EP1802615A1
(en)
*
|
2004-10-20 |
2007-07-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
|
CA2488325C
(en)
*
|
2004-11-22 |
2010-08-24 |
Apotex Pharmachem Inc. |
Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
|
|
EP2308870A3
(en)
|
2005-06-01 |
2011-10-19 |
UCB Pharma S.A. |
2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
|
|
EP1731149A1
(en)
*
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
|
WO2007031263A1
(en)
*
|
2005-09-15 |
2007-03-22 |
Ucb Pharma, S.A. |
4-substituted pyrr0lidin-2-0nes and their use
|
|
JP2007153755A
(ja)
*
|
2005-12-01 |
2007-06-21 |
Gifu Univ |
プロリン類縁体
|
|
JP2009518335A
(ja)
*
|
2005-12-07 |
2009-05-07 |
ユセベ ファルマ ソシエテ アノニム |
３−カルボキシ−２−オキソ−１−ピロリジン誘導体及びそれらの使用
|
|
US8338621B2
(en)
|
2005-12-21 |
2012-12-25 |
Ucb S.A. |
Process for the preparation of 2-oxo-1-pyrrolidine derivatives
|
|
LV13630B
(en)
*
|
2006-03-16 |
2007-12-20 |
Olainfarm As |
Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
|
|
ES2444009T3
(es)
*
|
2006-06-08 |
2014-02-21 |
Ucb Pharma, S.A. |
Co-cristales de pirrolidinonas
|
|
EA019757B1
(ru)
*
|
2006-06-15 |
2014-06-30 |
ЮСиБи ФАРМА ГМБХ |
Фармацевтическая композиция с синергетическим противосудорожным эффектом
|
|
WO2008021666A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
|
DK2076508T3
(da)
*
|
2006-10-18 |
2011-02-21 |
Pfizer Prod Inc |
Biaryl-ether-urinstof-forbindelser
|
|
WO2008103319A2
(en)
|
2007-02-16 |
2008-08-28 |
Ark Diagnostics, Inc. |
Compounds and methods for use in detecting gabapentin
|
|
WO2008132142A2
(en)
*
|
2007-04-27 |
2008-11-06 |
Ucb Pharma S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
|
US20090082422A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched levetiracetam
|
|
MX2010009222A
(es)
*
|
2008-03-03 |
2010-09-28 |
Ucb Pharma Sa |
Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
|
|
US7741327B2
(en)
*
|
2008-04-16 |
2010-06-22 |
Hoffmann-La Roche Inc. |
Pyrrolidinone glucokinase activators
|
|
US20110212944A1
(en)
*
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
|
EP2147911A1
(en)
|
2008-07-24 |
2010-01-27 |
ZaCh System S.p.A. |
Process for the preparation of levetiracetam
|
|
JP4644881B2
(ja)
|
2008-09-19 |
2011-03-09 |
高砂香料工業株式会社 |
ルテニウム錯体の製造方法
|
|
DK3260118T3
(da)
|
2008-10-16 |
2021-04-19 |
Univ Johns Hopkins |
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
|
|
EP2349335B1
(en)
|
2008-10-24 |
2013-08-07 |
ARK Diagnostics, Inc. |
Levetiracetam immunoassays
|
|
WO2010054009A1
(en)
*
|
2008-11-07 |
2010-05-14 |
Novabay Pharmaceuticals, Inc. |
Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
|
|
CN102215828A
(zh)
*
|
2008-11-18 |
2011-10-12 |
Ucb医药有限公司 |
包含2-氧代-1-吡咯烷衍生物的延长释放制剂
|
|
AU2009317280B2
(en)
*
|
2008-11-18 |
2014-03-06 |
Ucb Pharma, S.A. |
Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
|
|
FR2939311A1
(fr)
*
|
2008-12-08 |
2010-06-11 |
Oreal |
Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
|
|
EP2393483B1
(en)
|
2009-02-09 |
2017-06-28 |
UCB Biopharma SPRL |
Pharmaceutical compositions comprising brivaracetam
|
|
US8846411B2
(en)
*
|
2009-06-11 |
2014-09-30 |
Microgenics Corporation |
Derivatives, reagents, and immunoassay for detecting levetiracetam
|
|
WO2011015349A2
(en)
|
2009-08-07 |
2011-02-10 |
Ucb Pharma, S.A. |
Methods for enhancing the cognitive function
|
|
US7939676B2
(en)
|
2009-09-17 |
2011-05-10 |
Zach System S.P.A. |
Process for the preparation of levetiracetam
|
|
US8487591B1
(en)
|
2009-12-31 |
2013-07-16 |
Cirrus Logic, Inc. |
Power control system with power drop out immunity and uncompromised startup time
|
|
CA2778194C
(en)
*
|
2009-10-23 |
2016-07-12 |
Ucb Pharma, S.A. |
2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
|
|
PL389364A1
(pl)
|
2009-10-23 |
2011-04-26 |
Uniwersytet Jagielloński |
Nowe zastosowanie pochodnych 2-pirolidonu
|
|
EA202092673A3
(ru)
|
2010-02-09 |
2021-05-31 |
Дзе Джонс Хопкинс Юниверсити |
Способы и композиции для улучшения когнитивной функции
|
|
FR2961098A1
(fr)
|
2010-06-09 |
2011-12-16 |
Oreal |
Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
|
|
FR2961099B1
(fr)
|
2010-06-09 |
2012-06-15 |
Oreal |
Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
|
|
FR2961101B1
(fr)
|
2010-06-09 |
2013-01-25 |
Oreal |
Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
|
|
US8466297B2
(en)
|
2010-11-01 |
2013-06-18 |
Milan Soukup |
Manufacturing process for (S)-Pregabalin
|
|
EP3034079B1
(en)
|
2010-11-15 |
2018-01-10 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
|
BR112013020283A2
(pt)
*
|
2011-02-09 |
2016-07-19 |
Univ Johns Hopkins |
"uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
|
|
US8957218B2
(en)
|
2011-04-18 |
2015-02-17 |
Ucb Pharma S.A. |
2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
|
|
JP6162125B2
(ja)
|
2011-09-30 |
2017-07-12 |
タフツ・ユニバーシティ |
神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
|
|
MX353024B
(es)
*
|
2011-12-27 |
2017-12-18 |
Bio Pharm Solutions Co Ltd |
Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
|
|
TW201408293A
(zh)
*
|
2012-07-05 |
2014-03-01 |
Merz Pharma Gmbh & Co Kgaa |
(r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
|
|
TW201408294A
(zh)
*
|
2012-07-05 |
2014-03-01 |
Merz Pharma Gmbh & Co Kgaa |
(r)-苯基披喇瑟盪於治療帕金森氏症之用除
|
|
US9163055B2
(en)
|
2012-09-28 |
2015-10-20 |
Tufts University |
Methods for treating glaucoma using uridine diphosphate derivatives
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
US9738915B2
(en)
|
2012-12-07 |
2017-08-22 |
Merck Sharp & Dohme Corp. |
Biocatalytic transamination process
|
|
WO2014087367A2
(en)
*
|
2012-12-09 |
2014-06-12 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological diseases and its associated complications
|
|
EP2945942B1
(en)
|
2013-01-18 |
2018-05-09 |
ARK Diagnostics, Inc. |
Voriconazole immunoassays
|
|
US9920136B2
(en)
|
2013-02-13 |
2018-03-20 |
Ark Diagnostics, Inc. |
Posaconazole immunoassays
|
|
EA034135B9
(ru)
|
2013-03-13 |
2020-04-10 |
Тафтс Юниверсити |
Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
|
|
AR095442A1
(es)
|
2013-03-13 |
2015-10-14 |
Univ Tufts |
Derivados de nucleósido de uridina, composiciones y métodos de uso
|
|
AU2014228512A1
(en)
|
2013-03-15 |
2015-10-01 |
Agenebio, Inc. |
Methods and compositions for improving cognitive function
|
|
WO2014144663A1
(en)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
|
CN103342672B
(zh)
*
|
2013-07-02 |
2015-12-23 |
扬州大学 |
取代吡咯烷-2-酮的新合成方法
|
|
JP6465634B2
(ja)
*
|
2013-12-05 |
2019-02-06 |
株式会社日本触媒 |
環状アミド基含有重合体
|
|
JP6453632B2
(ja)
*
|
2013-12-05 |
2019-01-16 |
株式会社日本触媒 |
環状アミドアクリレート含有組成物およびその製造方法
|
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
KR20220049612A
(ko)
|
2014-01-21 |
2022-04-21 |
얀센 파마슈티카 엔.브이. |
대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
|
|
HUE053734T2
(hu)
|
2014-01-21 |
2021-07-28 |
Janssen Pharmaceutica Nv |
2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
|
|
CN104098497B
(zh)
*
|
2014-06-17 |
2016-04-13 |
王庚禹 |
一种新的酰胺类化合物
|
|
WO2016075082A1
(en)
|
2014-11-10 |
2016-05-19 |
Sandoz Ag |
Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
|
|
US20180021307A1
(en)
|
2015-02-20 |
2018-01-25 |
Ucb Biopharma Sprl |
Combination Treatment
|
|
WO2016191435A1
(en)
*
|
2015-05-25 |
2016-12-01 |
Peng Wang |
Processes to produce brivaracetam
|
|
CN106279074B
(zh)
*
|
2015-05-25 |
2018-06-26 |
苏州鹏旭医药科技有限公司 |
一种化合物及其制备方法和在合成布瓦西坦中的用途
|
|
CN106365986B
(zh)
*
|
2015-07-21 |
2019-01-08 |
苏州鹏旭医药科技有限公司 |
化合物及其制备方法和在合成布瓦西坦中的用途
|
|
US11384104B2
(en)
|
2015-06-19 |
2022-07-12 |
Centurion Biopharma Corporation |
Delivery systems for controlled drug release
|
|
JP6987384B2
(ja)
|
2015-06-19 |
2021-12-22 |
エージンバイオ， インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
|
ES2893301T3
(es)
|
2015-11-03 |
2022-02-08 |
Ucb Biopharma Sprl |
Proceso para preparar brivaracetam
|
|
WO2017076737A1
(en)
|
2015-11-03 |
2017-05-11 |
Ucb Biopharma Sprl |
Continuous process for preparing brivaracetam
|
|
CN106748748B
(zh)
*
|
2015-11-10 |
2021-08-24 |
成都国为生物医药有限公司 |
一种布瓦西坦的制备方法及其中间体
|
|
MA43532A
(fr)
|
2015-12-30 |
2018-11-07 |
Adamas Pharmaceuticals Inc |
Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
|
|
CN105646319B
(zh)
*
|
2015-12-30 |
2018-05-18 |
佛山市隆信医药科技有限公司 |
一种布瓦西坦的制备方法
|
|
EP3452447A4
(en)
|
2016-05-03 |
2019-12-18 |
The Regents of The University of California |
INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS
|
|
RU2629117C1
(ru)
*
|
2016-06-14 |
2017-08-24 |
Сизов Владимир Владимирович |
Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
|
|
CN107513031B
(zh)
*
|
2016-06-16 |
2022-08-02 |
上海医药集团股份有限公司 |
一种2-氧代-1-吡咯烷手性衍生物的制备方法
|
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
EP3571183B1
(en)
|
2017-01-20 |
2024-03-06 |
The Regents of the University of California |
3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
|
|
CN106866483A
(zh)
*
|
2017-02-05 |
2017-06-20 |
苏州鹏旭医药科技有限公司 |
布瓦西坦的晶型c及其制备方法
|
|
WO2018141276A1
(zh)
*
|
2017-02-05 |
2018-08-09 |
苏州鹏旭医药科技有限公司 |
布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
|
|
CN108503610B
(zh)
|
2017-02-24 |
2019-09-13 |
北京艾百诺医药股份有限公司 |
一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
|
|
CN108658831B
(zh)
*
|
2017-03-30 |
2021-11-05 |
江苏豪森药业集团有限公司 |
2-氧代-1-吡咯烷衍生物或其盐的制备方法
|
|
KR102582624B1
(ko)
|
2017-04-24 |
2023-09-22 |
테사로, 인코포레이티드 |
니라파립의 제조 방법
|
|
KR102642823B1
(ko)
|
2017-06-30 |
2024-03-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
모발 성장을 조절하기 위한 조성물 및 방법
|
|
CN111868039A
(zh)
|
2017-09-26 |
2020-10-30 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
CN107721896A
(zh)
*
|
2017-10-19 |
2018-02-23 |
丽珠集团新北江制药股份有限公司 |
一种布瓦西坦的中间体的制备方法
|
|
CN107793342A
(zh)
*
|
2017-10-19 |
2018-03-13 |
丽珠集团新北江制药股份有限公司 |
一种布瓦西坦的制备方法
|
|
CN111712511B
(zh)
|
2017-11-30 |
2024-07-16 |
拉德克斯公司 |
澳瑞他汀e衍生物的白蛋白结合产物
|
|
IL305268A
(en)
|
2017-11-30 |
2023-10-01 |
Centurion Biopharma Corp |
Maytansinoid-based drug delivery systems
|
|
WO2019152536A1
(en)
|
2018-01-30 |
2019-08-08 |
The Regents Of The University Of California |
Inhibitors of the wnt/beta-catenin pathway
|
|
CN108147988B
(zh)
*
|
2018-02-13 |
2020-10-02 |
扬州奥锐特药业有限公司 |
一种高手性纯度内酰胺化合物的制备方法
|
|
CN108530402B
(zh)
*
|
2018-04-10 |
2020-06-26 |
浙江工业大学 |
一种(R)-3-丙基-γ-丁内酯的制备方法
|
|
EP3566760A1
(en)
*
|
2018-05-07 |
2019-11-13 |
Universite Libre De Bruxelles |
Method for nucleating crystals from a solution in a capillary tube
|
|
CA3097818A1
(en)
|
2018-05-08 |
2019-11-14 |
UCB Biopharma SRL |
1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
|
|
US11414425B2
(en)
|
2018-06-19 |
2022-08-16 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
CN110615744B
(zh)
|
2018-06-20 |
2023-01-06 |
上海朴颐化学科技有限公司 |
一种布瓦西坦中间体及其制备方法
|
|
EP3813841B1
(en)
|
2018-06-29 |
2025-08-13 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
|
RU2699669C1
(ru)
*
|
2018-07-04 |
2019-09-09 |
Общество С Ограниченной Ответственностью "Валента - Интеллект" |
Новые составы N-карбамоилметил-4-фенил-2-пирролидона
|
|
BR112021001499A2
(pt)
|
2018-07-27 |
2021-04-27 |
California Institute Of Technology |
inibidores de cdk e usos dos mesmos
|
|
DK3867223T3
(da)
|
2018-10-17 |
2026-03-16 |
Univ California |
Prodrugs af alpha-ketoglutarat, alpha-ketobutyrat, alpha-ketoisovalerat og alpha-ketoisohexanoat og anvendelser deraf
|
|
EP3699173A1
(en)
|
2018-10-18 |
2020-08-26 |
California Institute of Technology |
Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
|
|
KR20210068591A
(ko)
|
2018-10-31 |
2021-06-09 |
주식회사 인투셀 |
융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
|
|
SG11202105863PA
(en)
|
2018-12-04 |
2021-07-29 |
Metys Pharmaceuticals AG |
Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
|
|
EP3944739A4
(en)
|
2019-02-25 |
2023-06-21 |
The Regents of the University of California |
METHOD OF FRAGMENTATION OF CARBON-CARBON BONDS
|
|
CN109932442A
(zh)
*
|
2019-03-04 |
2019-06-25 |
成都美域高制药有限公司 |
一种布瓦西坦异构体的检测方法
|
|
EP3947387B1
(en)
|
2019-03-25 |
2024-10-23 |
California Institute Of Technology |
Prmt5 inhibitors and uses thereof
|
|
CN114286675A
(zh)
|
2019-06-04 |
2022-04-05 |
海格生物科学有限责任公司 |
作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法
|
|
CN110357752A
(zh)
*
|
2019-08-15 |
2019-10-22 |
中国工程物理研究院化工材料研究所 |
一种快速制备均匀包覆含能材料的方法
|
|
RU2732245C1
(ru)
*
|
2019-08-30 |
2020-09-14 |
Ооо "Валента-Интеллект" |
Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
|
|
CN110551050A
(zh)
*
|
2019-09-02 |
2019-12-10 |
南通大学 |
一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
|
|
US10781170B1
(en)
|
2019-10-21 |
2020-09-22 |
Divi's Laboratories Ltd. |
Process for preparing Brivaracetam
|
|
AU2020407122A1
(en)
|
2019-12-20 |
2022-06-23 |
The Regents Of The University Of California |
Synthesis of compounds to promote hair growth
|
|
WO2021142132A1
(en)
|
2020-01-07 |
2021-07-15 |
The Trustees Of Princeton University |
Compositions and methods for treatment of disease by manipulation of serine metabolism
|
|
WO2021142221A1
(en)
|
2020-01-10 |
2021-07-15 |
The Regents Of The University Of California |
Compositions and methods for the treatment of neurodegenerative diseases
|
|
US20230174460A1
(en)
|
2020-04-21 |
2023-06-08 |
President And Fellowes Of Harvard College |
Afmt analogs and their use in methods of treating parkinson's disease
|
|
LV15614A
(lv)
*
|
2020-07-30 |
2022-02-20 |
Latvijas Organiskās Sintēzes Institūts |
2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
|
|
WO2022035805A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
CA3191163A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
|
CN116782894A
(zh)
*
|
2020-10-06 |
2023-09-19 |
D.E.肖研究有限责任公司 |
作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
|
|
EP4232161A1
(en)
|
2020-10-23 |
2023-08-30 |
Dana-Farber Cancer Institute, Inc. |
Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
AU2021409394A1
(en)
|
2020-12-21 |
2023-07-27 |
Cornell University |
Peptide-linked drug delivery system
|
|
WO2022150574A1
(en)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
|
US11400074B1
(en)
|
2021-02-01 |
2022-08-02 |
Divi's Laboratories Ltd. |
Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
|
|
US12559456B2
(en)
|
2021-02-03 |
2026-02-24 |
Suzhou Brighthope Pharma Tech Co., Ltd |
Method for preparing levetiracetam and intermediates thereof
|
|
US11384050B1
(en)
|
2021-02-03 |
2022-07-12 |
Vitaworks Ip, Llc |
Method for preparing levetiracetam and intermediates thereof
|
|
CN114948953A
(zh)
*
|
2021-06-29 |
2022-08-30 |
四川大学华西医院 |
一种杂原子取代芳香类化合物及其盐的用途
|
|
CN113511994B
(zh)
*
|
2021-08-16 |
2023-03-21 |
江苏八巨药业有限公司 |
一种左乙拉西坦的制备方法
|
|
CN114634437B
(zh)
*
|
2022-03-29 |
2023-05-30 |
武汉氟本氘合新材料科技有限公司 |
一种布瓦西坦的简易制备方法
|
|
US11884623B2
(en)
|
2022-05-23 |
2024-01-30 |
Divi's Laboratories Ltd. |
Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
|
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
|
CN119604494A
(zh)
|
2022-07-13 |
2025-03-11 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
US20260076939A1
(en)
*
|
2022-08-31 |
2026-03-19 |
Korea University Research And Business Foundation |
Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor
|
|
WO2024163711A1
(en)
|
2023-02-02 |
2024-08-08 |
Osmoses Inc. |
Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
|
|
CN116041240B
(zh)
|
2023-02-17 |
2024-04-09 |
扬州奥锐特药业有限公司 |
布立西坦中间体的不对称催化氢化合成方法
|
|
EP4431086A1
(en)
|
2023-03-16 |
2024-09-18 |
Adalvo Limited |
Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
|
|
US12590059B2
(en)
|
2023-03-28 |
2026-03-31 |
Suzhou Brighthope Pharmatech Co., Ltd |
Process for the production of levetiracetam
|
|
WO2025078883A2
(en)
|
2023-05-06 |
2025-04-17 |
Prepaire Labs Limited |
Organic compound (oxime) to combat chemical warfare agents
|
|
US12528770B2
(en)
|
2023-06-12 |
2026-01-20 |
Suzhou Brighthope Pharmatech Co., Ltd. |
Process for the production of levetiracetam and intermediates thereof
|
|
AU2024344058A1
(en)
|
2023-09-18 |
2026-04-02 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025072751A1
(en)
|
2023-09-29 |
2025-04-03 |
Battelle Memorial Institute |
Polymer nanoparticle compositions for in vivo expression of polypeptides
|
|
WO2025072893A1
(en)
|
2023-09-29 |
2025-04-03 |
Battelle Memorial Institute |
Polymer nanoparticle compositions for non-viral gene delivery
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025231452A1
(en)
|
2024-05-02 |
2025-11-06 |
Martinez Montemayor Michelle |
Ergosterol peroxide derivatives and uses thereof
|
|
WO2026030679A1
(en)
|
2024-08-01 |
2026-02-05 |
Osmoses Inc. |
Hollow fiber polymer membranes for fluid separation
|
|
WO2026060616A1
(en)
|
2024-09-20 |
2026-03-26 |
Fulcrum Therapeutics, Inc. |
Phenothiazine and phenoxazine calmodulin inhibitors and methods of use thereof
|
|
US20260090998A1
(en)
|
2024-10-02 |
2026-04-02 |
Battelle Memorial Institute |
Methods of using polymer nanoparticle compositions for treating a disease
|